Cantor Fitzgerald Weighs in on uniQure FY2025 Earnings

uniQure (NASDAQ:QURE) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of uniQure in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biotechnology company will post earnings per share of ($1.87) for the year. Cantor Fitzgerald has a “Overweight” rating and a $58.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

A number of other research analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of uniQure in a research report on Tuesday, December 10th. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research report on Tuesday. The Goldman Sachs Group lifted their price target on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.38.

uniQure Stock Performance

QURE opened at $15.29 on Thursday. The firm’s 50 day moving average is $12.39 and its 200-day moving average is $8.56. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. Point72 Asset Management L.P. boosted its holdings in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the last quarter. Walleye Capital LLC purchased a new stake in uniQure in the third quarter valued at $444,000. FMR LLC boosted its holdings in uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Sanders Morris Harris LLC grew its position in uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after purchasing an additional 34,034 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of uniQure during the 3rd quarter valued at about $7,360,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.